The United States Patent and Trademark Office (USPTO) has granted patent US12583857B2 for "Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines." The patent, assigned to PHEON THERAPEUTICS LTD, covers substituted pyrridinobenzodiazepines (PDDs) of formula (XVI) and their pharmaceutically acceptable salts, which are identified as useful medicaments, specifically as anti-proliferative agents. The patent was granted on March 24, 2026, with a filing date of December 21, 2023, and includes 18 claims.

This grant signifies the USPTO's recognition of novel intellectual property in the field of organic chemistry and pharmaceuticals. For entities operating in this space, particularly drug manufacturers and pharmaceutical companies, this patent establishes exclusive rights for PHEON THERAPEUTICS LTD concerning the claimed compounds. While this is a grant of a patent and not a regulatory rule imposing direct compliance obligations on other entities, it is crucial for companies involved in the research, development, or commercialization of similar anti-proliferative agents to be aware of this patent to avoid potential infringement issues.